Tags

Type your tag names separated by a space and hit enter

Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii.
Exp Ther Med. 2016 Sep; 12(3):1715-1718.ET

Abstract

The aim of the present study was to examine the clinical distribution and drug resistance of Acinetobacter baumannii infection, and provide evidence of clinical medication as well as the prophylaxis for the treatment of drug resistance bacteria. In total, 306 Acinetobacter baumanniis selected from routine culture were collected between January 2012 and December 2013, to analyze the distributions among clinical specimens and wards and their drug resistance state. Of the 306 Acinetobacter baumanniis, the main distribution of specimens was sputum, accounting for 77.78%. The distribution of administrative office was dominated by intensive care unit with a proportion of 40.0% in 2012, which rapidly increased to 60.9% in 2013, followed by neurosurgery, respiration medicine and orthopedics with proportions of 23, 12 and 9.0% in 2012 and 9.71, 8.74 and 3.88% in 2013, respectively. The Acinetobacter baumannii's drug resistance rate of Tazobactam and Piperacillin was increased from 68.0% in 2012 to 71.36% in 2013. At the same time, the drug resistance rate of imipenem was enhanced from 66.0% in 2012 to 72.81% in 2013. By 2013, the drug resistance rates of penbritin, ceftizoxime, cefotetan and macrodantin reached ≤100%. In conclusion, Acinetobacter baumannii mainly causes respiratory tract infection with severe drug resistance. The drug resistance of Acinetobacter baumannii was mainly manifested as multidrug resistance or even pan-drug resistance with an obvious increasing trend of tolerance. Thus, it is necessary to prevent and treat nosocomial infection, to minimize usage of antibiotics and to standardize medical operating, to reduce the increase in persistence.

Authors+Show Affiliations

Department of Pneumology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221000, P.R. China.Department of Pneumology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221000, P.R. China.Department of Pneumology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221000, P.R. China.Department of Pneumology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221000, P.R. China.Department of Pneumology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221000, P.R. China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27602085

Citation

Ren, Guangming, et al. "Analysis On Distribution Features and Drug Resistance of Clinically Isolated Acinetobacter Baumannii." Experimental and Therapeutic Medicine, vol. 12, no. 3, 2016, pp. 1715-1718.
Ren G, Zhou M, Ding N, et al. Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii. Exp Ther Med. 2016;12(3):1715-1718.
Ren, G., Zhou, M., Ding, N., Zhou, N., & Li, Q. (2016). Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii. Experimental and Therapeutic Medicine, 12(3), 1715-1718.
Ren G, et al. Analysis On Distribution Features and Drug Resistance of Clinically Isolated Acinetobacter Baumannii. Exp Ther Med. 2016;12(3):1715-1718. PubMed PMID: 27602085.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Analysis on distribution features and drug resistance of clinically isolated Acinetobacter baumannii. AU - Ren,Guangming, AU - Zhou,Min, AU - Ding,Ning, AU - Zhou,Ning, AU - Li,Qingling, Y1 - 2016/07/11/ PY - 2015/12/21/received PY - 2016/07/11/accepted PY - 2016/9/8/entrez PY - 2016/9/8/pubmed PY - 2016/9/8/medline KW - Acinetobacter baumanii KW - clinical distribution KW - drug resistance SP - 1715 EP - 1718 JF - Experimental and therapeutic medicine JO - Exp Ther Med VL - 12 IS - 3 N2 - The aim of the present study was to examine the clinical distribution and drug resistance of Acinetobacter baumannii infection, and provide evidence of clinical medication as well as the prophylaxis for the treatment of drug resistance bacteria. In total, 306 Acinetobacter baumanniis selected from routine culture were collected between January 2012 and December 2013, to analyze the distributions among clinical specimens and wards and their drug resistance state. Of the 306 Acinetobacter baumanniis, the main distribution of specimens was sputum, accounting for 77.78%. The distribution of administrative office was dominated by intensive care unit with a proportion of 40.0% in 2012, which rapidly increased to 60.9% in 2013, followed by neurosurgery, respiration medicine and orthopedics with proportions of 23, 12 and 9.0% in 2012 and 9.71, 8.74 and 3.88% in 2013, respectively. The Acinetobacter baumannii's drug resistance rate of Tazobactam and Piperacillin was increased from 68.0% in 2012 to 71.36% in 2013. At the same time, the drug resistance rate of imipenem was enhanced from 66.0% in 2012 to 72.81% in 2013. By 2013, the drug resistance rates of penbritin, ceftizoxime, cefotetan and macrodantin reached ≤100%. In conclusion, Acinetobacter baumannii mainly causes respiratory tract infection with severe drug resistance. The drug resistance of Acinetobacter baumannii was mainly manifested as multidrug resistance or even pan-drug resistance with an obvious increasing trend of tolerance. Thus, it is necessary to prevent and treat nosocomial infection, to minimize usage of antibiotics and to standardize medical operating, to reduce the increase in persistence. SN - 1792-0981 UR - https://www.unboundmedicine.com/medline/citation/27602085/Analysis_on_distribution_features_and_drug_resistance_of_clinically_isolated_Acinetobacter_baumannii L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1792-0981&volume=12&issue=3&spage=1715&aulast=Ren DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.